Vicore Pharma Holding Future Growth

Future criteria checks 2/6

Vicore Pharma Holding is forecast to grow earnings and revenue by 44.9% and 61.7% per annum respectively. EPS is expected to grow by 45.2% per annum. Return on equity is forecast to be -66.8% in 3 years.

Key information

44.9%

Earnings growth rate

45.2%

EPS growth rate

Biotechs earnings growth	42.7%
Revenue growth rate	61.7%
Future return on equity	-66.8%
Analyst coverage	Low
Last updated	27 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:6Y4 - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-332	-360	-360	4
12/31/2025	N/A	-337	-336	-354	5
12/31/2024	103	-166	-40	-116	2
9/30/2024	104	-196	-181	-181	N/A
6/30/2024	104	-200	-129	-129	N/A
3/31/2024	104	-213	-149	-149	N/A
12/31/2023	N/A	-311	-250	-250	N/A
9/30/2023	N/A	-260	-282	-282	N/A
6/30/2023	N/A	-265	-314	-314	N/A
3/31/2023	N/A	-261	-309	-306	N/A
12/31/2022	N/A	-288	-303	-300	N/A
9/30/2022	N/A	-308	-278	-275	N/A
6/30/2022	N/A	-337	-280	-277	N/A
3/31/2022	N/A	-342	-289	-289	N/A
12/31/2021	N/A	-296	-265	-265	N/A
9/30/2021	N/A	-274	-232	-229	N/A
6/30/2021	N/A	-213	-189	-186	N/A
3/31/2021	N/A	-167	-141	-138	N/A
12/31/2020	N/A	-147	-123	-120	N/A
9/30/2020	N/A	-116	-106	-106	N/A
6/30/2020	N/A	-103	-101	-101	N/A
3/31/2020	N/A	-105	-98	-98	N/A
12/31/2019	N/A	-93	-87	-87	N/A
9/30/2019	0	-79	-90	-88	N/A
6/30/2019	0	-71	-73	-71	N/A
3/31/2019	0	-38	-46	-44	N/A
12/31/2018	1	-22	-35	-33	N/A
9/30/2018	-1	-26	-13	-27	N/A
6/30/2018	0	-12	N/A	-24	N/A
3/31/2018	0	-22	N/A	-32	N/A
12/31/2017	1	-24	N/A	-28	N/A
9/30/2017	3	-8	N/A	-8	N/A
6/30/2017	3	-8	N/A	-7	N/A
3/31/2017	3	-7	N/A	-6	N/A
12/31/2016	1	-25	N/A	-21	N/A
9/30/2016	2	-6	N/A	N/A	N/A
6/30/2016	2	-6	N/A	N/A	N/A
3/31/2016	2	-5	N/A	N/A	N/A
12/31/2015	2	-5	N/A	-4	N/A
9/30/2015	2	7	N/A	N/A	N/A
6/30/2015	1	10	N/A	N/A	N/A
3/31/2015	1	12	N/A	N/A	N/A
12/31/2014	2	14	N/A	-3	N/A
9/30/2014	2	2	N/A	N/A	N/A
6/30/2014	2	0	N/A	N/A	N/A
3/31/2014	3	-1	N/A	N/A	N/A
12/31/2013	3	-2	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6Y4 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 6Y4 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 6Y4 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 6Y4's revenue (61.7% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: 6Y4's revenue (61.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 6Y4 is forecast to be unprofitable in 3 years.

Vicore Pharma Holding Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

No longer forecast to breakeven

No longer forecast to breakeven

Vicore Pharma Holding AB (Publ) Resumes VP02 Production

Recent updates

Vicore Pharma Holding AB (publ) to Report Q2, 2025 Results on Aug 22, 2025

Vicore Pharma Holding AB (publ), Annual General Meeting, May 06, 2025

New major risk - Shareholder dilution

Vicore Pharma Holding AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 782.138028 million.

Vicore Pharma Holding AB Initiates the Global, Randomized Phase 2B Aspre Trial Evaluating the Disease-Modifying Potential of Buloxibutid in Idiopathic Pulmonary Fibrosis

Less than half of directors are independent

Vicore Pharma Holding AB (Publ) Announces Board Appointments

Vicore Pharma Holding AB (Publ) Announces Maarten Kraan, as Board Member Declined Re-Election

Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis

No longer forecast to breakeven

Vicore Pharma Holding AB (publ) to Report Q4, 2024 Results on Feb 27, 2025

New minor risk - Share price stability

Vicore Pharma Holding AB (publ) Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates

Vicore Pharma Holding AB (publ) Appoints Bertil Lindmark as Chief Medical Officer

New minor risk - Share price stability

Vicore Pharma Holding AB (publ) to Report Q2, 2024 Results on Aug 22, 2024

Vicore Pharma Holding AB (publ), Annual General Meeting, May 07, 2024

Vicore Pharma Holding AB (publ) Provides Update Regarding Phase 1 Study of C106

New major risk - Revenue and earnings growth

Vicore Pharma Holding AB (publ) Reports Data from EndoPAT® Exploratory Trial

New major risk - Shareholder dilution

Vicore Pharma Holding AB (Publ) Announces Executive Changes

Vicore Pharma Holding AB (publ) Reports New 36-Week Data from the Air Trial Demonstrating Sustainable Disease Stimulating the Potential of A New Class of Drugs to Stop Disease Propose and Restate in IPF Patients

Vicore Pharma Holding AB (publ) to Report Q2, 2023 Results on Aug 24, 2023

Vicore Pharma Holding AB (publ) Announces First Patient Enrolled in COMPANION; a Digital Therapeutic Pivotal Study for Patients with Pulmonary Fibrosis

Vicore Pharma Holding AB (publ) Announces New Data from the IPF Air Trial Further Strengthening the Benefit-Risk Profile of C21

Vicore Pharma Holding AB (publ) Announces the Appointment of Nomination Committee

Vicore Selects New ATRAG as Next Drug Candidate

Vicore Pharma Holding AB (publ) Announces Positive Results for the Pilot Phase of the COMPANION study

Vicore Pharma Holding AB Announces C21 Promotes Vascular Function in Humans

Vicore Pharma Holding AB (Publ) Provides an Update on the Attract-3 Covid-19 Trial

Vicore Pharma Holding AB (publ) Announces Initiation of First-In-Human Trial with the Novel ATRAG C106

Vicore Pharma Holding AB (publ) Amends Primary Endpoint to Accelerate the Phase 3 Trial in COVID-19 Patients

Vicore Launches COMPANION, A Clinical Study Investigating the Benefit of Digital Therapy on Anxiety in Patients with Idiopathic Pulmonary Fibrosis

Vicore Pharma Holding AB (Publ) Announces Plans to Initiate A Clinical Trial with C21 in PAH

Vicore Pharma Holding AB (Publ) Announces Advancing its First New Chemical Entity from the VP03 Program to a First in Human Phase 1 Trial

Vicore Pharma Holding Announces Data from an Interim Analysis of the Phase 2 Proof-of-Concept Study in IPF

Vicore Pharma Holding AB (publ) Starts Dosing of First Covid-19 Patients in the Global Phase 3 Trial ATTRACT-3

No longer forecast to breakeven

High number of new directors

Vicore Pharma Holding AB (publ) Announces FDA Acceptance for Pivotal Phase 3 Trial of C21 in COVID-19

Vicore Pharma Holding AB (Publ) Announces Top Line Data from A Phase Ii Study of Its Oral Angiotensin II Type 2 Receptor (AT2R) Agonist C21 in Patients with Systemic Sclerosis and Raynaud's Phenomenon

Vicore Pharma Holding AB (Publ) Resumes VP02 Production

Vicore Pharma Holding AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 336 million.

Vicore Pharma Holding AB Announces Positive Data from Phase II Study Attract in Patients with Covid-19 Published Online

New 90-day high: €2.82

Vicore Pharma Holding Reports an Expanded Data Analysis to Follow Up the Encouraging Top Line Data from the ATTRACT

Vicore Pharma Holding AB (Publ) Announces Last Patient Last Visit in the Mechanistic Phase II Study with C21 in Systemic Sclerosis

Vicore Pharma Reports Positive Top Line Data from the ATTRACT clinical study in patients with COVID-19

New 90-day low: €1.78

Vicore Pharma Holding AB Recruits the First Patient in the Phase II Proof-Of-Concept Study in Idiopathic Pulmonary Fibrosis

Vicore Pharma Holding AB (publ) to Report Fiscal Year 2020 Final Results on Apr 15, 2021

Vicore Pharma Holding AB (publ) to Report Q2, 2021 Results on Aug 26, 2021

Vicore Pharma Holding AB (Publ) Announces Completion of Patient Enrollment in the Covid-19 Attract Trial

Vicore Pharma Holding AB (publ) Announces Robust Effects of VP01 in Human Idiopathic Pulmonary Fibrosis Lung Tissue

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies